激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌的治疗现状

Current treatment status of HR+/HER 2-advanced breast cancer

王羽 ¹邵彬 ²刘洋 ³王松 ⁴张建国⁵

扫码查看

作者信息

1. 150086 黑龙江省牡丹江市肿瘤医院头颈乳腺三科;哈尔滨医科大学附属第二医院乳腺外科
2. 150086 黑龙江省牡丹江市肿瘤医院头颈乳腺三科
3. 150086 黑龙江省牡丹江市肿瘤医院核医学科
4. 150086 黑龙江省牡丹江市肿瘤医院肿瘤内二科
5. 哈尔滨医科大学附属第二医院乳腺外科
折叠

摘要

目前,乳腺癌的发病率已位居世界首位,激素受体阳性(HR+)/人表皮生长因子受体2阴性(HER2-)晚期乳腺癌病人预后较差.以往,治疗的药物主要为第三代芳香化酶抑制剂(AI)和氟维司群.近几年,开启了内分泌联合细胞周期蛋白依赖性激酶4/6(CDK4/6)抑制剂治疗时代.不同CDK4/6抑制剂其相关不良事件有所不同,需评估病人身体状况而制定治疗方案,但普遍存在中性粒细胞减少.依维莫司、阿培利司、西达本胺等都是二线治疗药物.

Abstract

At present,the incidence of breast cancer has been the first in the world,and hormone receptor-positive(HR+)/human epidermal growth factor receptor 2-negative(HER2-)advanced breast cancer has seriously affected the prognosis of patients.In the past,the therapeutic drugs were mainly third-generation aromatase inhibitors(AI)and fulvestrant.In recent years,the era of endocrine therapy combined with cyclin-dependent kinase4/6(CDK4/6)inhibitors has begun.Different CDK4/6 inhibitors have different related adverse events,and they need to evaluate the physical condition of patients and develop a treatment plan,but neutropenia is prevalent.Everolimus,Alpelisib,and Chidamide are second-line therapeutic drugs.

关键词

激素受体阳性/晚期乳腺癌/CDK4/6抑制剂

Key words

hormone receptor positive/advanced breast cancer/CDK4/6 inhibitor

引用本文复制引用

出版年

2024

临床外科杂志

中华医学会湖北分会

临床外科杂志

CSTPCD

影响因子：0.716

ISSN：1005-6483

段落导航